NIH Funding Opportunities

Sidebar

NIAID: HIV Vaccine Research and Design (HIVRAD) Program (P01, Clinical Trial Not Allowed) PAR-24-037

The purpose of this Notice of Funding Opportunity (NOFO) is to support multi-component, multi-disciplinary projects that address scientific questions relevant to AIDS prophylactic vaccine discovery research. Extensive evaluation of vaccine concepts in non-human primate models may be included.

First Available Due Date: March 13, 2024
Expiration Date: March 13, 2026

PAR-24-037


Notice of Special Interest (NOSI): Ending the HIV Epidemic (EHE)

The objective of this Notice of Special Interest (NOSI) is to solicit applications proposing research that is grounded in implementation science and can address the goals of the Ending the HIV Epidemic in the U.S. (EHE) initiative. The overall objective of EHE is to address the ongoing public health crisis with goals of first reducing the number of incident infections in the U.S. by 75% by 2025, and at least 90% by 2030, compared to the baseline infection rate in 2017. Projects will leverage research-community collaborations and scientific advances in HIV prevention, diagnosis, treatment, and outbreak response to advance the EHE goals, using innovations to tailor strategies for the multi-level barriers and strengths in communities disproportionately impacted by HIV.

NOT-AI-23-070

First Available Due Date: January 07, 2024
Expiration Date: January 10, 2024


NIDA REI: Reaching Equity at the Intersection of HIV and Substance Use: Novel Approaches to Address HIV Related Health Disparities in Underserved Racial/Ethnic Populations (R01 Clinical Trial Optional) RFA-DA-23-023

This Funding Opportunity Announcement (FOA) is a part of NIDA’s Racial Equity Initiative (REI), with goals that include promoting racial equity in NIDA’s research portfolio. The purpose of this FOA is to stimulate new observational and intervention research on structural factors, organizational practices, policies, and other social, cultural, and contextual influences that lead to inequities at the intersection of HIV and substance use among underserved racial and/or ethnic minority populations affected by persistent HIV disparities.

RFA-DA-23-023

Application Due: November 14, 2023


NIH Funding Opportunity: Implementation Science for Cancer Control in People Living with HIV in Low- and Middle-Income Countries (U01 Clinical Trial Optional)(RFA-CA-23-033): 

The purpose of this Notice of Funding Opportunity (NOFO) is to support Implementation Science for Cancer Control in People Living with HIV (PLWH) in Low- and Middle-Income Countries (LMICs) to accelerate the integration of evidence-based cancer control interventions for PLWH by leveraging existing HIV treatment and prevention infrastructure.

RFA-CA-23-033

Application Due: December 15, 2023


NIH- Basic/Translational Research on Health Disparities in Underrepresented People Living with HIV (PLWH) and Cancer (R01 Clinical Trial Not Allowed)

Through this funding opportunity announcement, the National Cancer Institute (NCI) intends to focus on the biological interactions of cancer health disparities in people living with HIV (PLWH) from underrepresented minority groups through basic mechanistic or translational studies to investigate how HIV interacts with health disparities to promote both non-AIDS and AIDS-defining cancer initiation, progression, and the resulting pathogenic disease sequelae.

RFA-CA-22-056

Open Date (Earliest Submission Date): November 15, 2022
Expiration Date: December 16, 2023


NIH- Basic/Translational Research on Health Disparities in Underrepresented People Living with HIV (PLWH) and Cancer (R21 Clinical Trial Not Allowed)

Through this funding opportunity announcement, the National Cancer Institute (NCI) intends to focus on the biological interactions of cancer health disparities in people living with HIV (PLWH) from underrepresented minority groups through basic mechanistic or translational studies to investigate how HIV interacts with health disparities to promote both non-AIDS and AIDS-defining cancer initiation, progression, and the resulting pathogenic disease sequelae.

RFA-CA-22-057

Open Date (Earliest Submission Date): November 15, 2022
Expiration Date: December 16, 2023


NIAID: Transgender People: Immunity, Prevention, and Treatment of HIV and STIs (R21 Clinical Trial Not Allowed)

The purpose of this Funding Opportunity Announcement (FOA) is to support hypothesis-generating research in transgender people with the objective of characterizing the biological and immunological impact of the interventions (hormones, drugs and surgical) used for gender reassignment and their impact on susceptibility to HIV and other sexually transmitted infections (STI).

PAR-22-186

First Available Due Date: December 07, 2022

Expiration Date: December 08, 2024


NIAID - Notice of Special Interest (NOSI): Towards Developing a Cure for HBV in HIV/HBV Co-Infection

The Notice of Special Interest (NOSI) seeks to fill scientific gaps needed to (a) inform HBV cure strategies by furthering our understanding of unique challenges impacting HBV and HIV co-infected hosts; and (b) advance the discovery and development of novel HBV interventions that are safe and achieve a cure in HIV and HBV co-infected individuals.

NOT-AI-22-043

First Available Due Date: September 05, 2022

Expiration Date: May 08, 2025


NIAID- Notice of Special Interest (NOSI): Sustained Release of Antivirals for Treatment or Prevention of HIV or Treatment of Latent TB/HBV (SRATP)

The purpose of this Notice is to encourage new applications to support further development of a diverse and comprehensive portfolio of SR/LA products for prevention and treatment of HIV. SR/LA antiretroviral products will have a minimum window of protection of three (3) months from either a single dosing (injection, oral administration) or continuous dosing regimen (implant, transdermal patch, etc.) to reflect current state of SR/LA drug market for HIV treatment or prevention.

NOT- AI-22-042

First Available due date: September 7, 2022

Expiration Date: May 8, 2025

At a Glance